
1. Conventional Drug Discovery Methods
2. Bioinformatics & Computational Biology
3. Training & Consultation
4. Custom Solutions
Future Targeted Services:
1. Literature to Pathways mining
2. Reaction Mining
3. Microarray Data Analaysis |
|
1. Conventional Drug Discovery Methods
RASA provides a wide array of methods for conventional drug discovery to match the complex and urgent needs of industry. RASA offers high quality non-turnkey approach which emphasizes the importance of expert knowledge of the target field and structural domain. RASA offers services in designing and optimizing virtual library, scaffold hopping, predicting bioactivity, toxicity and ADME properties, protein-protein, protein-ligand and ligand-ligand interactions.
 |
 |
 |
| |
Phamacological Activity Prediction:
The design of new medical drugs possessing desired physical and chemical properties is a challenging task in any pharmaceutical industry. If one goes by the traditional approach, then the designer will need to test a very large number of molecules, and look for the desired pharmacological property that can needs to be present in the drug to be formulated. Therefore it is very useful to have tools that can predict and discriminate the pharmacological activity of a given molecular compound so that the designer needs to do his laboratory experiments in a well directed manner, such that they are they are directed to those molecular groups in which there is a high probability of finding new compounds with desired properties.
RASA’s specializes in predicting all possible bioactivity (> 3,000 including drug targets and disease). Our algorithm contains several statistical models for disease and associated drug targets.
Deliverables
A detailed delivery report for Phamacological Activity Prediction consists of:
1.
A detailed report of the molecule's pharmacological activity with graphical output 2. Report powered with extensive literature references.
Read More + (PDF) |
|
 |
 |
 |
 |
 |
 |
| |
Toxicity Prediction:
A huge investment is associated with the designing and synthesis of a drug. It is true that these drugs give us a better life. However serious side effects have been observed in some drugs, that raise a social question and resulting in the withdrawal of the drug from the market.The cost incurred in case of a drug that has to be withdrawn from market due to toxic effects is unimaginable. In such cases the cost of development of the drug increases by a big margin. We can minimize the expenditure by determining potential toxicity problems as early as possible. Toxicity if predicted at an early stage, for example before the molecule is synthesized will drastically reduce the cost of the drug which is otherwise incurred due to drug-failure. Thus the use of predictive toxicology is called for. Various types of in-silico studies can be performed to predict side-effects of the molecule, thus giving us firsthand information about the possible unwanted properties of the molecule, hence allowing us to refrain from the synthesis of such molecules as possible drugs. Quantitative structure-activity relationships (QSARs), relating mostly to specific chemical classes, have long been used for this purpose, and exist for a wide range of toxicity endpoints.
RASA’s toxicity prediction service predicts all possible Toxicity (> 150). We use several statistical models for Toxicity and associated drug targets for toxicity thus providing you with a detailed report of the molecules properties.
Deliverables
1. A detailed report of the molecule's toxicity with graphical output.
2. Report powered with extensive literature references.
Read More + (PDF) |
|
 |
 |
 |
|